Efficacy and tolerability of tafluprost in patients with glaucoma

Written by Shulgina N.A., Khokhlova A.S., Rogacheva E.V., Doronina L.V., Sereda T.G.

  UDK: 617.7-007.681-085.225.2 | Pages: 29–31 | Full text PDF | Open PDF 


Objective. The objective of the study is to give the assessment to the drug ‘Taflotan’ in patients with different stages of primary open-angle glaucoma (POAG). Methods. The clinical efficacy of the prostaglandin analogue without preservative - eye drops "Taflotan" (tufluprost 0.0015 %) was studied in the protocol of treatment of 34 patients 47-80 years old with POAG I-III st. The observation period is 6 months. Results. Taflotan demonstrated a sufficient hypotensive effect: from 19.9 % in the far-advanced to 23.8 % in the initial stages of the disease, 94.1 % of patients were well tolerated without causing general and local negative reactions. Conclusions. To preserve visual functions, stabilize the glaucoma process and tear production in the initial stages, tuflotan should be used as an independent drug, and in the far-reaching stage of POAG in combination with α2-adrenomimetic (brimonidine).

Links to authors:

N.A. Shulgina1, A.S. Khokhlova1, 2, E.V. Rogacheva2, L.V. Doronina2,
T.G. Sereda2
1 Pacific State Medical University (2 Ostryakova Ave. Vladivostok 690950 Russian Federation),
2 Vladivostok Clinical Diagnostic Center (169/171 Svetlanskaya St. Vladivostok 690001 Russian Federation)

1. Astakhov S.Yu., Tkachenko N.V. ‘Taflotan’ – the first analogue of prostaglandin F2α without preservative: advantages in treating patients with primary open-angle glaucoma // Ophthalmology Journal. 2016. No. 2. P. 59–68.
2. Egorov E.A., Astakhov Yu.S., Erichev V.P., et al. Efficacy and safety of eye drops tafluprost 0.0015% without preservative in patients with ophthalmic hypertension and open-angle glaucoma // Clinical Ophthalmology. 2015. No. 1. P. 1–6.
3. Erichev V.P., Ambartsumyan K.G. Features of antihypertensive therapy for glaucoma patients with preparations without preservatives // Ophthalmology. 2012. No. 4. P. 194–196.
4. Erichev V.P., Ambartsumyan K.G., Fedorov A.A. Clinical and morphological evidence of the effect of preservatives on the eye surface with primary open-angle glaucoma // Glaucoma. 2009. No. 1. P. 23–26.
5. The morbidity of Russian population in 2010. Statistics. Part IV. М.: Federal Research Institute for Health Organization and Informatics of Ministry of Health of the Russian Federation, 2011. 46 p.
6. National guidance on glaucoma: for medical practitioners / edited by E.A. Egorov, Yu.S. Astakhov, V.P. Erichev. М.: GEOTAR-Media, 2015. 452 p.
7. Petrov S.Yu., Safonova D.M. Pharmacological properties, experimental studies and clinical use of tafluprost // Pacific Medical Journal. 2015. No. 3. P. 11–13.
8. Hommer A., Kimmich F. Switching patients from preserved prostaglandin – analog monotherapy to preservative-free tafluprost // Clin. Ophthalmol. 2011. No. 5. P. 623–631.
9. Swymer C., Neville M.W. Tafluprost: the first preservative-free prostaglandin to treat open-angel glaucoma and ocular hypertension // Ann. Pharmacother. 2012. Vol. 46, No. 11. P. 1506–1510.
10. Takagi Y., Nakajima T., Shimazaki A. [et al.]. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, a san ocular hypotensive drug // Exp. Eye Res. 2004. Vol. 74, No 4. P. 767–776.
11. Terminology and guidelines for glaucoma. European Glaucoma Society, 2014, 4rd edition. 195 p.
12. Uusitalo H., Pillunat L.E., Ropo A., Phase I.I.I.S.I. Efficacy and safety of tafluprost 0,0015 % versus latanoprost 0,005 % eye drops in open-angel glaucoma and ocular hypertension: 24-month results of a randomized double-masked phase III stady // Acta ophthalmologica. 2010. Vol. 88, No 1. P. 12–19.


Founded in 1997  |  Editions in a year: 4, Articles in one issue: 30 |  ISSN of print version: 1609-1175  |  Ind.: 18410 (Agency "Rospechat’")  |  Edition: 1000 c.